Crossmark

HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women

Crossref DOI link: https://doi.org/10.1186/s13058-018-1072-1

Published Online: 2018-11-20

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wege, Anja Kathrin

Chittka, Dominik

Buchholz, Stefan

Klinkhammer-Schalke, Monika

Diermeier-Daucher, Simone

Zeman, Florian

Ortmann, Olaf

Brockhoff, Gero http://orcid.org/0000-0001-8398-8349
Funding

Funding for this research was provided by:

Deutsche Forschungsgemeinschaft (BR1873/9-1)
License Information

Text and Data Mining valid from 2018-11-20
More Information

Article History

Received: 17 April 2018

Accepted: 1 November 2018

First Online: 20 November 2018

Ethics approval and consent to participate

: In compliance with the Helsinki Declaration and in accord with the statements given by the local ethics committee of the University of Regensburg, ethics approval and informed consent was not required for this study.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below